Investors have been left with mixed emotions regarding the stock price performance over the year, as it’s been a mixed bag. This year’s metric has recorded a Price decrease of -35.28%. However, over the past six months, we’ve seen a stronger performance of -41.30%. The price of CDTX leaped by -36.01% over the last 30 days. And in the last five days, it has fallen by -37.69%.
In terms of market performance, Cidara Therapeutics Inc had a fairly uneven. The highest value for the stock in the past year was $1.48 on 05/23/23, and the lowest value was recorded at $0.59 on 04/22/24.
52-week price history of CDTX Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Cidara Therapeutics Inc’s current trading price is -65.28% away from its 52-week high, while its distance from the 52-week low is -13.34%. The stock’s price range during this period has varied between$0.59 and $1.48. The Cidara Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 3.7 million for the day, a figure considerably higher than their average daily volume of 0.7 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Cidara Therapeutics Inc (CDTX) has experienced a quarterly decline of -28.12% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 46.57M.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 0.7508, with a change in price of -0.1892. Similarly, Cidara Therapeutics Inc recorded 772,412 in trading volume during the last 100 days, posting a change of -26.91%.
CDTX’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for CDTX stands at 0.54. Similarly, the long-term debt-to-equity ratio is also 0.41.
CDTX Stock Stochastic Average
Cidara Therapeutics Inc’s raw stochastic average for the past 50 days is presently 1.90%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 1.90%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 2.71% and 4.61%, respectively.
